Specialized RCM Advocacy for Rheumatology

Defending buy and bill yield and neutralizing infusion denials

Rheumatology carries the highest dollar exposure of any office based specialty. A single biologic infusion can represent more revenue than a full day of office visits, and it can be denied for a reason that has nothing to do with the clinical decision behind it. Unit math on the drug, a missing product identifier, a prior authorization that expired partway through a treatment course: any one of these turns a delivered and documented infusion into an unpaid one.

Buy and bill makes the exposure worse, because the practice has already purchased the drug. A denied claim is not deferred revenue in rheumatology. It is inventory the practice paid for and cannot recover. WeBill Health maintains carrier specific rules across the biologic categories rheumatology practices infuse, and coding experts apply them to every claim before submission.

The Rheumatology Forensic Leakage Map

1. J Code Unit Math and Product Identifier Reporting

Drug codes are defined in billing units that rarely match the vial size or the dose the clinician ordered. A dose documented in milligrams has to be converted to the billing unit the code specifies, and the conversion differs by drug. Practices that report the dose instead of the units underbill dramatically, and practices that report vials instead of units overbill into recoupment territory.

Product identifier reporting compounds it. Payers increasingly require the drug identifier alongside the code, in the correct format and unit of measure. A claim that carries the right code, the right units and a malformed identifier still denies, and it denies as a coding error rather than as a formatting one, which sends most billing teams looking in the wrong place.

2. Drug Wastage and the Discarded Amount Requirement

Single dose vials produce wastage, and the wastage is billable when documented correctly. CMS requires modifiers that report either the discarded amount or the affirmative absence of any discarded amount, and the requirement now applies to single dose container drugs broadly rather than to a short list. Claims submitted without the applicable modifier are rejected.

Practices that never learned to report wastage are giving away a recoverable amount on every partially used vial. Practices that report it without documenting the discarded volume in the record are creating audit exposure on the same claims. Both patterns show up in a rheumatology accounts receivable file within a single quarter.

3. Prior Authorization Expiry and Step Therapy Mid Course

A rheumatology prior authorization is approved for a defined period and a defined number of administrations. Treatment courses outlast authorizations routinely, and the claim that falls outside the window denies even though every earlier claim in the same course paid. Payer mandated biosimilar switching creates the same break, because the new product is a different code and the existing authorization does not cover it.

Infusion administration coding sits on top of all of this. Only one initial administration code is reportable per encounter per access site, with subsequent and additional hour codes layered correctly, and an evaluation and management service delivered the same day requires its own modifier to survive bundling.

The WeBill Health Defense for Rheumatology

Unit conversion verified against the code definition on every drug claim, so the billed units reflect the documented dose rather than the vial or the order.
Product identifier and wastage modifier review before submission, with discarded amounts reconciled against the administration record.
Authorization lifecycle tracking across the full treatment course, so an expiring approval is renewed ahead of the next infusion instead of discovered through a denial.
Administration code hierarchy applied per encounter, with same day evaluation and management protected by correct modifier use.

Rheumatology Performance Benchmarks

98%

Clean claim rate across every specialty WeBill Health defends

48 Hours

Submission guarantee on every claim

40%

Reduction in accounts receivable within 90 days

7 to 14 Days

Reimbursement velocity across your top five payers

25%

Average increase in collections within six months, through specialty specific coding and reduced days in accounts receivable

Frequently Asked Questions

Why do biologic infusion claims get denied when the prior authorization was approved?

The most common reason is that the authorization expired or its administration limit was exhausted partway through the treatment course. Authorizations are approved for a defined window and a defined number of administrations, and a course that runs longer than the approval produces denials on later claims even though earlier claims in the same course paid.

How are drug billing units calculated for rheumatology infusions?

Each drug code defines its own billing unit, and that unit rarely matches the vial size or the ordered dose. The documented dose has to be converted into the units the code specifies before the claim is submitted. Reporting the milligram dose or the number of vials instead of the billing units causes both underpayment and overpayment depending on the drug.

Does drug wastage have to be reported on rheumatology claims?

Yes. CMS requires a modifier reporting either the discarded amount from a single dose container or the affirmative absence of any discarded amount. The discarded volume must also be documented in the patient record. Claims missing the applicable modifier are rejected, and claims reporting wastage without supporting documentation create audit exposure.

Can an office visit be billed on the same day as an infusion?

Yes, when the evaluation and management service is significant and separately identifiable from the infusion itself and the documentation supports it. The claim requires the appropriate modifier to survive bundling. A visit that consists only of assessing the patient for that day's infusion generally does not qualify.

Audit Your Rheumatology Revenue

A Revenue Health Audit reviews your infusion claims for unit conversion errors, missing wastage modifiers, authorization gaps and bundling losses. WeBill Health quantifies what is recoverable in your existing accounts receivable and what is exposed to recoupment.

Request Your Rheumatology Revenue Audit